Serum levels ofinsulin-like growth factor-I (IGF-I) and insulin-like growth factor-binding protein-1 (IGFBP\x=req-\ 1) have been determined by radioimmunoassay in the maternal circulation (n = 91) and in the umbilical artery (n = 56) and vein (n = 90) of man. In both the umbilical artery and vein, the concentration of serum IGF-I showed an inverse correlation with birthweight (P < 0\m=.\005and P < 0\m=.\001 respectively); the mean serum IGF-I levels in the small-for-gestational-age (SGA) group were significantly higher than those in average\x=req-\ for-gestational-age (AGA) neonates (P <0\m=.\01and P < 0\m=.\001 respectively). However, maternal serum IGF\x=req-\ I showed no association with birthweight and there was no significant difference between the SGA and AGA groups. These observations imply that the production of IGF-I in the maternal and fetal compartments is independent and that there is unlikely to be transfer of IGF-I across the placenta. Serum IGFBP-1 levels in both maternal and umbilical cord blood (artery and vein) showed an inverse relation to birthweight (P <0\m=.\001,P<0\m=.\005 and P<0\m=.\001 respectively).
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INTRODUCTION
Insulin-like growth factors I and II (IGF-I and IGF-II) are mitogenic peptides which are believed to be growth hormone (GH) dependent (Burrin, Paterson, Sharp & Yeo, 1987) . They can promote tissue growth and differentiation, and have insulin-like metabolic effects (Guler, Zapf & Froesch, 1987) . These effects are mediated via two classes of receptors on target cell surfaces (Rechler & Nissley, 1985) . Type I receptors also bind insulin at high concentrations (Ullrich, Gray, Tarn et al. 1986 (Bohn & Kraus, 1980; Beli, Patel, Haies et al. 1985) (Ritvos, Ranta, Jalkanen et al. 1988 ) while others have suggested that it might enhance the action of IGFs (Elgin, Busby & Clemmons, 1987) .
During pregnancy, maternal circulating IGF-I con¬ centrations increase progressively (Wilson, Bennett, Adamson et al. 1982; Hall, Enberg, Hellen et al. 1984) . In fetal blood, IGF-I can be detected from as early as 15 weeks of gestation (Ashton, Zapf, Einschenk & MacKenzie, 1985) . At term, fetal IGF-I levels show a positive correlation with birthweight and gestational age (Wilson et al. 1982; Gluckman, Johnson-Barrett, Butler et al. 1983; Ashton et al. 1985) . In the fetal rat, there is a decrease in IGFs following experimental growth retardation produced by ligation of uterine vessels (De Prins, Hill, Fekete et al. 1984 (Foley, De Philip, Perricelli & Miller, 1980) . However, IGFBP-1 levels in the maternal circulation reveal an inverse correlation with delivered weight, being increased in pregnant subjects who deliver lowbirthweight infants (Howell, Perry, Choglay et al. 1985; Hall, Hasson, Lundin et al. 1986 ). Furthermore, the serum concentrations of IGFBP-1 are also increased in pregnancies complicated by proteinuric pre-eclampsia, a condition that is frequently associated with intra¬ uterine growth retardation (Howell, Golde, 1989) Ciba-Geigy Ltd) at concentrations between 5 and 1000 pg/1 was used to obtain a standard curve. The minimum detection limit of the assay was 10 pg/1. Non¬ specific binding (NSB) of l25I-labelled IGF-I in the absence of antiserum was 3-5-5-5%. The intra-assay coefficients of variation were 4-9% at 345 pg/1 and 10-2% at 185 pg/1. The interassay coefficients of vari¬ ation (n = 8) were 71% at 345 pg/1 and 13-4% at 185 pg/1. There was no cross-reaction with insulin (Sigma), IGF-II (Ciba-Geigy Ltd) or IGFBP-1, puri¬ fied as previously described (Wang et al. 1991) .
RESULTS
In umbilical cord blood, both arterial and venous IGF-I levels showed an inverse correlation with birth¬ weight (P<0005 and P<0001 respectively) (Fig. 1) .
The mean concentration of umbilical cord serum IGF-I in the SGA group was significantly higher than that in AGA infants (Table 1) . By contrast, no associ¬ ation was found between maternal serum IGF-I levels (Fig. 1) . Cord serum IGFBP-1 was higher in SGA neonates than in the AGA group, but maternal IGFBP-1 showed no significant differ¬ ence between the two birthweight groups (Table 1 ). In the SGA group, the levels of IGFBP-1 in the cord artery and vein were substantially higher than those in the maternal circulation, but this difference was not significant (P>0-05, Fisher's exact probability test).
In all situations the concentration of IGF-I and IGFBP-1 in the umbilical artery was similar to that in the umbilical vein and there was a close association between them (P< 0-0001) ( Table 2 ). In both maternal and umbilical cord serum (artery and vein), IGFBP-1 levels were positively correlated with IGF-I levels (P<0-01, P<00005 and <0-0001, respectively).
Maternal serum IGFBP-1 concentrations were related to those in the umbilical artery and vein (P< 0-005 and < 0-02 respectively). There was no correlation between maternal serum IGF-I and umbilical arterial IGF-I levels; maternal IGF-I levels were positively associated with those in umbilical vein (P<005).
DISCUSSION
The present results confirm previous findings that maternal serum IGFBP-1 levels are inversely associ¬ ated with birthweight (Howell et al. 1985; Hall et al. 1986 ). They also demonstrate, for the first time, that the same association is seen in fetal serum. Thus, if the functional significance of the increased IGFBP-1 is to inhibit the action of IGF-I, then this phenomenon applies equally in both the maternal and the fetal compartments.
The bulk of the circulating IGFBP-1 in pregnancy is believed to be synthesized by decidualized endo¬ metrium (Rutanen, Menabawey, Isaka et al. 1986; Bell, 1989) . It has been proposed that the increased IGFBP-1 may protect the endometrium from further invasion by trophoblast, acting via inhibition of IGF-I receptors in placental membranes and thereby restricting IGF-I action (Pekonen, Suikkari, Makinen & Rutanen, 1988) . It would be attractive to speculate that the maternal factor in the control of fetal growth is partly mediated by the decidua, acting via synthesis of IGFBP-1. However, the present studies show that the relationship between delivered weight and both IGFBP-1 and IGF-I is more striking in the fetal circu¬ lation than in the maternal circulation (Table 1) . Since the only route by which decidual products could reach the fetus is via the maternal circulation and placental transfer, it seems unlikely that the decidua can play a primary role.
In the present study, IGF-I levels in both umbilical artery and vein were inversely related to birthweight, and cord serum IGF-I levels were significantly increased in the SGA group. These findings are in marked contrast to those of previous investigators, most of whom have reported that IGF-I levels are relatively low in the fetal circulation and show a posi¬ tive correlation with birthweight (Wilson et al. 1982; Gluckman et al. 1983; Ashton et al. 1985) . Reduced IGF levels have also been shown in cord serum from human SGA neonates (Foley et al. 1980; Aleem, Moharam, Schulman et al. 1990) (Han, D'Ercole & Lund, 1987) , the observation that many fetal tissues can secrete IGF-I in organ culture (Hill, Crace, Nissley et al. 1985; Swenne, Hill, Strain & Milner, 1987) and the wide distribution of IGFs in fetal tissues (Hill, Clemmons, Wilson et al. 1989 ). The latter studies further imply that IGF-I may stimulate growth via autocrine or paracrine actions at the site of production. During pregnancy there is a progressive increase in circulating levels of IGF-I; this appears to be indepen¬ dent of pituitary GH secretion (Wilson et al. 1982; Hall et al. 1984) . It is possible that the increased IGF-I plays a role in the regulation of placental growth; this is supported by the observation that cultured placental stromal cells respond to exogenous IGF-I (Fant, Munro & Moses, 1986) . The rapid decline in IGF-I levels postpartum (Franklin, Pepperell, Rennte & Cameron, 1979) suggests that the placenta and/or the fetus may secrete substances which stimulate maternal IGF-I production. Candidates include placental lactogen and, in particular, placental GH (Frankenne, Closset, Gomez et al. 1988 ). However, the present results show only a weak association between maternal and umbilical cord serum IGF-I levels, and no relation¬ ship between maternal serum IGF-I levels and fetal birthweight. This implies that the production of IGF-I in the maternal and fetal compartments is independent and that there is unlikely to be significant transfer of IGF-I across the placenta.
The fact that IGFBP-1 and IGF-I are identically distributed in human fetal tissues during the second trimester suggests that the action of IGF-I on tissue growth and differentiation may be modulated by IGFBP-1 at the tissue level (Hill et al. 1989) . This is further supported by the observation that, prior to 26 weeks gestation, the major binding protein for IGF-I in fetal serum is IGFBP-1 (D'Ercole, Wilson & Underwood, 1980 (Chard, 1989) .
If the present demonstration of increased levels of IGF-I in association with SGA is correct, then it is possible that this is secondary to the increase in IGFBP-1. The mechanism would be the same as that which applies to some steroids and steroid-binding proteins in pregnancy (e.g. cortisol-binding globulin leads to an increase in the total circulating cortisol). The overall effect is association of low-birthweight infants with high circulating IGF-I and IGFBP-1 levels. If circulating bound IGF-I is biologically inactive and cannot bind to receptors on fetal tissues, the rise of IGFBP-1 could be the primary cause of growth retardation.
Whether circulating IGF-I and IGFBP-1 play a direct role in fetal growth still requires further investi¬ gation. Thus, while it is very likely that fetal growth is influenced by an interaction amongst IGF-I, IGFBP-1 and IGF-I receptors at the local tissue level, the cir¬ culating concentrations of IGF-I and IGFBP-1 may only indirectly reflect these events.
